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Thickenera b s t r a c t
Locust bean gum (LBG) is a galactomannan polysaccharide used as thickener in infant formulas with the
therapeutic aim to treat uncomplicated gastroesophageal reﬂux (GER). Since its use in young infants
below 12 weeks of age is not explicitly covered by the current scientiﬁc concept of the derivation of
health based guidance values, the present integrated safety review aimed to compile all the relevant pre-
clinical toxicological studies and to combine them with substantial evidence gathered from the clinical
paediatric use as part of the weight of evidence supporting the safety in young infants below 12 weeks
of age. LBG was demonstrated to have very low toxicity in preclinical studies mainly resulting from its
indigestible nature leading to negligible systemic bioavailability and only possibly inﬂuencing tolerance.
A standard therapeutic level of 0.5 g/100 mL in thickened infant formula is shown to confer a sufﬁciently
protective Margin of Safety. LBG was not associated with any adverse toxic or nutritional effects in
healthy term infants, while there are limited case-reports of possible adverse effects in preterms receiv-
ing the thickener inappropriately. Altogether, it can be concluded that LBG is safe for its intended ther-
apeutic use in term-born infants to treat uncomplicated regurgitation from birth onwards.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction ical process in healthy infants, it usually starts at 2–3 weeks of ageRegurgitation is a characteristic symptom of uncomplicated
gastro-oesophageal reﬂux (GER) occurring as a common physiolog-(Vandenplas, 2009). It is reported that 50% of normal healthy
infants regurgitate at least once per day with associated discom-
fort, and 20% of the caregivers are looking for a medical assistance
to that phenomenon, primarily to lower parents anxiety and
strengthen their reassurance (Lightdale et al., 2013; Vandenplas,
2009). In more severe cases, excessive regurgitation can possibly
lead to insufﬁcient nutrient intake, failure to thrive and an
increased risk of health problems such as respiratory illness
(Vandenplas et al., 1997). In the context of uncomplicated but per-
sistent GER, one of the recommended approaches is the use of die-
tary interventions employing thickening agents or thickened infant
formulas to decrease the number of troublesome regurgitation
(Vandenplas et al., 1997, 2009). Such kind of dietary interventions
are most often based on slowly or non-digestible polysaccharide
food components (cereals, starch, guar gum, soy ﬁbre, locust bean
gum, which is also designated as carob bean gum). Among those
thickening agents, the food additive locust bean gum (LBG) is
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formulas prescribed to treat GER (or thickener to be added to food).
To exert a beneﬁcial effect on reﬂux, LBG-thickened formulas in
general contain an average level situated at 0.5 g/100 mL of LBG.
A clear distinction is made between GER and GERD (gastro-oesoph-
ageal reﬂux disease), since GERD is present when the reﬂux of gas-
tric contents causes troublesome symptoms and/or complications
and can also have different underlying pathophysiological causes
(a.o. neurologic impairment, obesity, congenital oesophageal dis-
ease, cystic ﬁbrosis) requiring a more speciﬁc medical treatment
(Vandenplas et al., 2009). In order to avoid the masking of more
severe pathophysiological causes, LBG-thickened formulas are
therefore only prescribed by Health Care professionals to healthy
term infants with uncomplicated GER.
To date LBG has been evaluated by different expert groups of
competent food safety authorities for its use as thickener or stabi-
lizer in a range of various foodstuffs aimed for the general popula-
tion (Joint FAO/WHO Expert Committee on Food Additives, EU
Scientiﬁc Committee on Food, US Food and Drug Administration).
The main detailed evaluations have been conducted by the Joint
FAO/WHO Expert Committee on Food Additives (JECFA) in the sev-
enties and, the latest one in 1981, mainly referred to in vitro and
in vivo animal data (JECFA, 1981). On that occasion, the JECFA allo-
cated a non-numerical Acceptable Daily Intake (ADI) ‘not speciﬁed’
that applies to substances with very low toxicity.
According to the scientiﬁc concept when deriving health-based
guidance values (Acceptable or Tolerable Daily Intake), such ADI
(or TDI) covers the overall population only from 12 weeks onwards
(Larsen et al., 1997; Ostergaard and Knudsen, 1998; SCF, 1998a;
World Health Organization, 2009). Likewise, since the general
guidance is not to use additives in foods for infants and young chil-
dren, and given that the use of LBG as a therapeutic dietary thick-
ener in healthy term infants was not considered for safety
evaluation at that time, the innocuousness of this food additive
has up to now never been put into perspective of that population
(0–12 weeks old) for which also data generated in paediatric trials
conducted with LBG should be taken into consideration. In absence
of an extended safety evaluation, the European Union (EU) Scien-
tiﬁc Committee on Food (SCF) considered the use of LBG as thera-
peutic agent acceptable in view of the demonstrated beneﬁts in the
treatment of GER (SCF, 2003).
The present integrated safety review aims to discuss and update
the current evidence obtained from the toxicological tests and, to
evaluate to what extent their outcome is relevant to address the
safety of LBG for healthy term infants below 12 weeks of age.
The additional safety and tolerance evidences from paediatric data
have now been integrated as part of the total weight of evidence to
conﬁrm the safety and tolerability of LBG in healthy term infants
treated by dietary interventions for uncomplicated gastro-oesoph-
ageal reﬂux.2. Chemical aspects
Locust bean gum (LBG, C.A.S 9000-40-2, Einecs 232-541-5) is
obtained from the endosperm seed of the locust/carob tree (Cerato-
nia siliqua (L.) Taub) of the plant family of Leguminosae. The seeds
are generally prepared either by thermal, mechanical or by chem-
ical treatment and then the germ is eliminated. The next steps are
milling and screening of the endosperm. The gum may be washed
with ethanol or isopropanol to control microbiological load. Com-
mercialized LBG is standardized with sugars for reactivity and vis-
cosity, and complies with the JECFA and EU speciﬁcations as
summarized in Table 1 (European Commission, 2012; JECFA,
2008). The prepared gum is a white to yellowish, nearly odourless
powder. The substance consists of high molecular weightpolysaccharides (50,000–3,000,000 daltons) consisting of at least
75% galactomannans. The general chemical structure is presented
in Fig. 1. The high molecular weight polysaccharides are composed
of the galactomannan units consisting of a linear chain of (1? 4)-
linked b-D-mannopyranosyl units (mannopyranose) with (1? 6)-
linked a-D galactopyranosyl residues (galactopyranose) as side
chains. The mannose and galactose contents have been reported
as 73–86% and 27–14%, respectively (mannose:galactose ratio of
approximately 4:1). Galactomannans are commonly found in other
gums such as guar, tara or cassia gum but with differences in man-
nose to galactose ratios. LBG is coded as INS/E 410 according to
food additives numbering.
LBG is commonly used in various foodstuffs as a food additive
with thickening, stabilizing, emulsifying or gelling properties. As
indicated above, its important thickening properties have been
extensively employed in infant formulas in the context of the die-
tary management of infant regurgitation for more than 20 years.
3. Scientiﬁc evaluations, regulatory context and uses in baby
foods
At international level, the Joint FAO/WHO Expert Committee on
Food Additives (JECFA) evaluated the safety of LBG in 1981 (JECFA,
1981). Considering the very low toxicity proﬁle of LBG observed
mainly in vitro and in animal studies, the committee allocated a
non-numerical ADI ‘not speciﬁed’. However, as for now the JECFA
committee did not consider the use of LBG as therapeutic ingredi-
ent in Foods for Special Medical Purposes especially in infants
below 12 weeks of age, having the consequence that LBG is only
authorized in the Codex Alimentarius as basic technological thick-
ener in infant formula up to 0.1 g/100 mL, but not approved for use
at sufﬁciently high levels to be effective as a therapeutic thickener
(therapeutic dosage of approximately 0.5 g/100 mL).
In the European Union, LBG up to 0.1 g/100 mL was assessed by
the Scientiﬁc Committee on Food (SCF) and, as a result, it was
authorized for technological purposes in follow-on formulas for
older infants in good health (SCF, 2003). Its use is also approved
up to 1 g/100 g in weaning foods (SCF, 2003). The SCF speciﬁcally
evaluated the use of LBG up to 1 g/100 mL as thickener in the con-
text of infant formulas and follow-on formulas aimed for term
infants in good health and in Foods for Special Medical Purposes
(FSMP) (SCF, 1998b, 2003). The committee considered the available
clinical evidences of beneﬁts and safety, and concluded that LBG
was acceptable for use up to 1 g/100 mL (10 g/L) for its use in FSMP
when prescribed under medical supervision to treat gastro-
oesophageal reﬂux (GER) (SCF, 1998b, 2003). As a result, LBG at
this level was authorised for this purpose by EU legislation. In Rus-
sia, LBG is allowed as in the EU (CU Regulation 029/2012).
In other jurisdictions, LBG is approved for use in standard infant
formula, follow-on formula or infant foods. In Australia and New
Zealand, LBG is authorized up to 0.1 g/100 mL in infant formula
and up to 1 g/100 g in food for infants (FSANZ, 2013). In Korea,
the use of LBG in infant formula and follow-on formula is autho-
rized according to the Quantum Satis principle meaning the lowest
level to achieve the technological function.
In the US, the use of LBG is addressed in 21 CFR 184.1343, 21
CFR 582.7343 and in the reviews of the Centre for Food Safety &
Applied Nutrition of the Food and Drug Administration (FDA).
Based on these references, LBG could be used in infant formula
as a stabiliser and thickener at a level not exceeding 5 g/L. How-
ever, infant formula with LBG is not on the market in the US. There-
fore, a pre-market infant formula notiﬁcation is required (US Food
and Drug Administration (FDA, 1972).
In China, the food safety standard on additives (GB 2760-2011)
allows an LBG level for infant and young children formula up to
0.7 g/100 ml. The standard is under revision and, if adopted
Table 1
EU and JECFA speciﬁcations for locust (carob) bean gum.
EU JECFA
Molecular weight 50,000–3,000,000 50,000–3,000,000
Galactomannan content Not less than 75% Not less than 75%
Galactose, mannose Passes test Not reported
Loss on drying Not more than 15% (150 C, 5 h) Not reported
Ash Not more than 1.2%, (at 800 C) Not more than 1.2%, (at 800 C)
Protein (N  6.25) Not more than 7% Not more than 7%
Acid-insoluble matter Not more than 4% Not reported
Starch Not detectable Not detectable
Heavy metals Not reported Not more than 0.002%
Arsenic Not more than 3 mg/kg Not reported
Lead Not more than 2 mg/kg Not more than 2 mg/kg
Mercury Not more than 1 mg/kg Not reported
Cadmium Not more than 1 mg/kg Not reported
Ethanol & isopropanol Not more than 1%, single or in combination Not more than 1%, single or in combination
Fig. 1. General chemical structure of locust bean gum, where n indicates the
number of galactomannan unit repeats.
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FSMP intended for infants and young children.
Comparable to the current status in the Codex Alimentarius, no
other jurisdictions other than China, the EU, Korea and Russia has
explicitly granted LBG use-levels effective as therapeutic agent in
foods for particular nutritional uses (e.g. FSMP).
Currently, AR formulas with an LBG level of up to 0.5 g/100 ml
and intended for infants from birth onwards are on the market
world-wide in at least 60 countries. This includes countries that
do not have speciﬁc legislative provisions to allow this level. This
could be due to the fact that the composition (including additives)
of FSMP products at Codex level has not been regulated in detail
before. Furthermore, it may also be due to the acceptance by the
medical professionals (experts on the treatment of anti-regurgita-
tion) and due to the national perception of the status of FSMP prod-
ucts (medicinal-like products).
4. Toxicological studies
In the context of the toxicity data presented in this part, it
should be emphasized that harmonized guidelines on chemical
toxicity testing only started to be implemented during the mid-
eighties. Therefore, not all studies on LBG were per se conducted
according to harmonized guidelines on chemicals testing (i.e. FDA
or OECD guidelines). However, more recent studies with high qual-
ity standards (in vitro genotoxicity, acute, sub-acute, sub-chronic
and chronic/carcinogenicity studies) were conducted by the US
National Toxicology Program (NTP) in the context of a cancer bio-
assay on LBG. Those studies did cover most of the recommended
endpoints stated in the harmonized guidelines. Since these studies
were ﬁnalized after the latest JECFA evaluation they were not
included in the latest JECFA toxicological monograph.4.1. Digestibility and ADME (Absorption, Distribution, Metabolism &
Excretion)
The galactomannans present in LBG and related gums are well
recognized components of dietary ﬁbres known to be resistant todigestive juices or enzymes in the human gastrointestinal tract
(Trowell et al., 1976). This occurs independently of the speciﬁc
mannose to galactose ratio, since humans do not possess endoge-
nous mannosidases. For instance, galactomannans were shown to
be stable in artiﬁcial gastric juice (Nurnberg and Bleimuller,
1981). LBG and related galactomannan-containing gums are there-
fore expected for their greatest part to be excreted unchanged in
the faeces. On the other hand, a small proportion of LBG and
related gums could be fermented by intestinal microbiota, but
are in general expected to be largely excreted unchanged in the
faeces. This is demonstrated for LBG in the studies cited hereafter.
In an in vitro study of Semenza (1975), no evidence of hydrolysis
of the gum was obtained following incubations with human gastric
juice, duodenal juice plus bile, pancreatic juice and succus enteri-
cus in absence or presence of rabbit small intestine membrane
enzymes. The additional evidences from in vivo studies further
indicate that LBG is not subject to direct action of enzymatic
hydrolysis within the intestine, but a marginal reduction in the
galactomannan chain length could be observed.
In a study by Robaislek (1974), LBG was not considered a source
of bioavailable calories in weanling Sprague–Dawley rats upon
exposure via the diet up to 2 g/d of LBG for 10 days, based on com-
parison of the carcass weight gain. In a study of Krantz et al. (1948)
it was demonstrated in rats that daily feeding 33% wheat ﬂour or
LBG with 67% cocoa butter for 2.5 days, the latter resulted in glyco-
gen accumulation in the liver, but far less efﬁcient compared to the
wheat ﬂour group.
Towle and Schranz (1975) demonstrated that rat large intesti-
nal microbiota partially hydrolysed LBG in vitro after conditioning
to LBG in the diet for three weeks. In a digestibility study con-
ducted by Tsay and Whistler (1975) with male and female rats,
fed 1% LBG, for 18 h, within 30 h 85–100% of mannose was
excreted via the faeces. It was reported that a decrease in chain
length of galactomannan may have occurred through the action
of microbiota, whereas liberation of galactose units was not
determined.
In a study performed by Vohra et al. (1979), it was reported that
the digestibility of the diet in newly weaned Sprague–Dawley rats
was not altered following the exposure to a soybean–corn meal
diet containing 2% LBG (equal to 2400 mg/kg bw/day) for 36 days.
To sum up, in vitro and in vivo studies have investigated LBG
digestibility and ADME-related endpoints and these were reviewed
in the toxicological evaluations of LBG performed by JECFA. Since
then, no new evidence on this endpoint has been generated in
the public domain. Of critical importance for the weight of evi-
dence on the innocuousness of LBG in young infants, is that the
above mentioned studies demonstrated negligible systemic avail-
ability of LBG. It appears that this feature is shared with other
gums containing galactomannans (cassia gum, tara gum) that
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independently of the speciﬁc mannose to galactose ratio. In addi-
tion, without signiﬁcant hydrolysis, it is estimated very unlikely
that the entire high molecular weight non-hydrolysed galactoman-
nan chains (50,000–3,000,000 daltons) constituting LBG will cross
the intestinal barrier of a neonate or young infant. Indeed, even
for lower molecular weight ﬁbres such as the oligosaccharides sim-
ilar to the ones of human milk (i.e. galacto-oligosaccharides less
than 1000 daltons), only a minor percentage (<1%) was shown to
be absorbed as intact molecule indicating that large scale absorp-
tion is very unlikely to occur (Engfer et al., 2000). In case a theoret-
ical hydrolysis occurs to a low extent in the gut of the neonate, the
resulting oligosaccharides and monosaccharides constituted of
mannose and to a lesser extent of galactose would be expected
to be absorbed and, enter the normal physiological and metabo-
lism pathways that are known to be already active in the neonatal
period (Brown et al., 2009; Kliegman and Sparks, 1985).
4.2. Acute toxicity
These studies were aimed to capture any potential acute toxic-
ity in various animal species exposed to LBG.
As part of the dose range-ﬁnding studies conducted in the con-
text of a carcinogenesis bioassay of the NTP, Fisher 344 rats and
B63CF1 mice of both sexes, consisting of 5 animals per group,
received a single dose of LBG equal to 0.3, 0.77 or 1.09 g/kg in
the diet (NTP, 1982). Mortality or any other compound-related
effects were not reported to occur during the observation period
of 15 days. Oral LD50 values for gavage in various species have
been reported to be as high as 13, 10, 5 and 9 g/kg bw for mice,
hamster, rat and rabbit, respectively (Maxwell and Newell, 1972).
Another unpublished gavage study included in the JECFA report
determined an LD50 equal to 13 g/kg bw for rat.
Overall, the compound has been shown to have very low acute
oral toxicity either when administered in the diet or through oral
gavage in several animal species.
4.3. Sub-acute toxicity studies
In the study by Vohra et al. (1979) cited earlier, no treatment-
related effects on growth have been reported in rats fed a soy-
bean-corn meal diet containing 2% LBG (equal to 2400 mg/kg bw/
day) for 36 days.
In a separate study of Mallett et al. (1984), male Sprague–Daw-
ley rats were exposed ad libitum to a diet containing 50 g/kg LBG
(equal to 6000 mg/kg bw/day) for 28 days. The body weight fol-
lowing LBG exposure was not affected. The weight of the caecal
contents and the caecal wall was reported to be increased follow-
ing the exposure to LBG compared to animals fed a puriﬁed diet.
The observed effect on caecal enlargement is not unique to LBG
but rather a general adaptive physiological phenomenon as a con-
sequence of the fermentation of dietary ﬁbres leading to the pro-
duction of large amounts of short chain fatty acids that have an
osmotic effect on the caecal content in animal studies (Demigne
et al., 2008, 1989; Garthoff et al., 2010; Mallett et al., 1985;
Mazur et al., 1990; Til and Bar, 1998; Wang et al., 2010). The inves-
tigators demonstrated in vitro that exposure to LBG resulted in a
signiﬁcant increase of the in vitro activity of caecal microbial
enzymes including azoreductase, b-glucosidase, nitroreductase,
nitrate reductase and urease. The observed increased enzyme
activity in vitro illustrates the physiological fermentation process
of indigestible polysaccharides as a result of the microbiota
activity.
Comparable results were obtained in the study of Evans et al.
(1992), where rats were given a diet containing LBG (9600 mg/
kg bw/day) versus a diet free from ﬁbre or a diet containingpuriﬁed cellulose for 2 weeks. No treatment-related effects on
body weight were reported. Similarly to the Vohra study, the
weight of the caecal contents as well and the caecal weight were
found to be signiﬁcantly increased after LBG treatment. In addition,
exposure to LBG was indicated to result in an increased water con-
tent of the faeces. According to the authors, the rate of hepatic total
lipid and cholesterol synthesis was signiﬁcantly lower in groups
treated with LBG compared to those exposed to a basal diet or a
cellulose-free diet. In addition, LBG was also reported to signiﬁ-
cantly decrease the level of lipids in rat liver compared to the basal
and cellulose free diet. Furthermore, liver and serum cholesterol
(i.e. non-HDL cholesterol) levels were indicated to be signiﬁcantly
decreased after LBG treatment.
A ﬁrst series of dose range-ﬁnding experiments was initiated to
identify adequate dosing regimen for the cancer bioassay. The
studies used male and female F344 rats and B63CF1 mice and
the animals were given a diet containing 0, 6300, 12,500, 25,000,
50,000 or 10,0000 ppm LBG (equal to 756, 1500, 3000, 6000 or
12,000 mg/kg bw/day for rats and administered by gavage 1260,
2500, 5000, 10,000 or 20,000 mg/kg bw/day for mice, respectively)
for a period of 2 weeks (NTP, 1982). No compound related-effects
on survival, body weight and on histopathology were reported to
occur following LBG treatment.
The neonatal piglet is generally considered a relevant animal
model to evaluate the safe use of food ingredients in infant for-
mula, as the physiology of digestion is similar to that of humans
(Moughan et al., 1992). The short-term effects of LBG on bacterio-
logical and morphological characteristics of the small intestine of
newly weaned piglets were studied by Van Nevel et al. (2005).
The animals were given a control diet in the absence or presence
of 1% LBG (equivalent to 1000 mg/kg bw/day, based on an assumed
intake of 0.133 kg feed per kg body weight) for 11 or 12 days. No
adverse effects were reported by the authors. No effect on intesti-
nal morphology and histological parameters were observed in
presence of LBG, besides some changes in the apoptotic index of
villi and the mitotic index of crypts. Both were slightly but statis-
tically signiﬁcantly decreased in the crypts of the proximal jeju-
num following administration of LBG diet but not in the distal
jejunum, although the authors underlined a great variability in
the numeration in the proximal part. The effect is not considered
to be of toxicological relevance since the cell renewal balance of
intestinal mucosa (death/proliferation) is not expected to be
affected which is also supported by the absence of histopatholo-
gical changes. On the fermentation parameters, only changes in
acetic acid and n-butyric acid in caecal contents were noted. No
other LBG related effects were observed.
4.4. Sub-chronic toxicity studies
Til et al. (1974) examined the general condition, behaviour, sur-
vival, growth, food intake, haematology, blood biochemistry and
urinalysis in male and female rats exposed to 0, 1, 2, or 5% LBG
in their diet (equal to 0, 900, 1800 and 4500 mg/kg bw/day, respec-
tively) for a period of 90 days (cited in JECFA toxicological mono-
graphs on LBG). No treatment-related effect was reported to
occur with the exception that at the highest LBG dosage the glu-
cose level was reported to be increased to some extent. Gross
and microscopic examination revealed an increase in the relative
weight of the caecum following exposure to 2% and 5% LBG. How-
ever, as discussed earlier in this paper, it was concluded by the
committee that this increase is not of toxicological relevance since
this is a known effect of high dietary ﬁbre levels causing an osmo-
tic effect. Other pathological changes attributable to ingestion of
the gum were not observed according to the JECFA evaluation.
In another NTP study, male and female Fisher 344 rats and
B6C3F1 mice were exposed to 0, 6300, 12,500, 25,000, 50,000 or
L. Meunier et al. / Regulatory Toxicology and Pharmacology 70 (2014) 155–169 159100,000 ppm LBG (0–10% in the diet, equal to 0, 567, 1125, 2250,
4500 or 9000 mg/kg bw/day for rats and 1260, 2500, 5000,
10,000 or 20,000 mg/kg bw/day for mice, respectively) for
13 weeks (Melnick et al., 1983; NTP, 1982). In the rat experiments,
one female fed the intermediate dose of 1125 mg/kg bw/day died
during the study. In the mice experiments, two male mice died
(one in the control group and one in the 20,000 mg/kg bw/day
group) and two female mice died (10,000 and 20,000 mg/kg bw/
day groups) as a result of undeﬁned accidental causes that were
not attributed to the compound. Based on clinical observations
and histopathological analyses, it was concluded that there were
no relevant compound-related effects observed.
4.5. Chronic toxicity studies
The JECFA toxicological monograph on LBG reports a study of
Carlson and Domanski (1980) in which 50 Fisher 344 rats of both
sexes were exposed to 0, 25,000 or 50,000 ppm LBG in the diet
(equal to 0, 1250 or 2500 mg/kg bw/day, respectively) for a period
of 103 weeks. No treatment-related effects on body weights, sur-
vival, or gross or microscopic lesions were observed. In addition,
50 male and 50 female Charles River albino rats received a 5% alpha
cellulose containing diet (control) or a diet supplemented with 2 or
5% LBG (equal to 1000 and 2500 mg/kg bw/day, respectively). Rats
were treated for a period of 24 months. The body weights of female
rats fed 2% LBG were reported to be signiﬁcantly increased at inter-
mediate weeks of LBG exposure but not at termination of the
study. Increased body weights were observed only in week 13 in
female rats exposed to 5% LBG in the diet. Numerous signiﬁcant
differences in food consumption were observed during the studies,
which were attributed to spillage of the control diet. As a result, the
changes in body weight were expected but considered of no toxi-
cological relevance. Some of the haematological parameters
(reticulocytes count, haemoglobin, segmented neutrophils and
lymphocytes) were signiﬁcantly different at the intermediate
time-point of six months but the differences were no longer
observed at termination of the study. Some differences in relative
organ weights were observed which were ascribed to the highly
variable values for these parameters in young rats and the fact that
all the animals may not have been exactly at the same age at sac-
riﬁce. Of major importance, no signiﬁcant treatment-related effects
on gross or microscopic pathology were reported.
In the context of NTP carcinogenicity bioassay on LBG, the
chronic effects of LBG were investigated in groups of 50 male
and 50 female Fisher 344 rats and B6C3F1 mice (Melnick et al.,
1983; NTP, 1982). Animals were treated with 0, 2.5 or 5% LBG
added to the diet (equal to 0, 1250 or 2500 mg/kg bw/day for rats
and 0, 3750 or 7500 mg/kg bw/day for mice, respectively) for
103 weeks after which observation continued for another one or
two weeks, without LBG administration. The average body weight
of rats and mice fed LBG was reported not to be signiﬁcantly differ-
ent compared to the control animals with the exception that the
body weight of male mice dosed 5% LBG was lower than the body
weight of control mice. Based on clinical examinations, no com-
pound-related effects were observed for treated rats or mice. No
signiﬁcant differences in survival between treated and control ani-
mals were observed.
Another chronic toxicity study was run in another species
(dogs) with a less well characterized LBG/guar gum preparation
(Cox et al. (1974) cited in JECFA toxicological monograph on
LBG). Five male and ﬁve female dogs were administered 0, 1, 5,
or 10% (equal to 0, 250, 1250 or 2500 mg/kg bw/day, respectively,
based on an assumed intake of 0.025 kg feed/kg bw/day) of a pre-
cooked mixture of LBG and guar gum at unknown ratios for
30 weeks. There was no evidence for adverse haematological,
urinary, gross and histopathological and ophthalmologicaltreatment-related effects. Hypermobility and soft and bulky stools
were reported to be observed after exposure to 10% (2500 mg/
kg bw/day) of the LBG and guar gum mixture. However, these
effects were considered most likely of no toxicological signiﬁcance
and caused by the unphysiologically high ﬁbre content of the diet.
In addition, the level of digestibility following the exposure to 10%
of the gummixture was reported to be reduced in male and female
dogs.
4.6. Reproductive toxicity and teratogenicity
An unpublished three-generation reproduction study was cited
in the JECFA toxicological monograph on LBG (Domanski et al.,
1980). In that study CD Charles River albino rats were fed 2 or
5% (1000 or 2500 mg/kg bw/day) LBG versus a control group
receiving 5% alpha methylcellulose. At each generation the paren-
tal animals received the test diet for 11 weeks prior to mating, ges-
tation and weaning phase. Two or three litters were raised per
generation and the second litter was used to produce the following
generation. Statistically signiﬁcant decreases in premating body
weight gain in the F0 females fed 2% LBG and in the ﬁnal body
weight in the females fed 5% LBG were observed. Some differences
in organ weight ratios were observed which were ascribed to the
highly variable values for these parameters in young rats and the
fact that all animals may not have been at the same age at sacriﬁce.
Of main importance, no signiﬁcant treatment-related effects on
reproductive indices or gross or microscopic pathology were
observed.
The JECFA toxicological monograph also mentions teratogenic-
ity experiments conducted by Morgareidge (1972). The test sub-
stance was administered through the oral route via intubation to
adult female rats and mice (13–1300 mg/kg bw/day, GD 6–15),
hamsters (10–1000 mg/kg bw/day, GD 6–10) and rabbits (9–
910 mg/kg bw/day, GD 6–18). Those studies did consistently dem-
onstrate the absence of teratogenic effect of LBG up to the highest
dosage tested in the different species. Although at concentrations
of 910 mg/kg bw/day in rabbits and 1300 mg/kg bw/day in mice
induced some mortality in the dams. This effect on mortality
remains of uncertain toxicological relevance since it was not
retrieved in rats and hamsters or even not correlated with gross
pathological ﬁndings at autopsy except slight haemorrhage in the
small intestine of rabbits.
4.7. In vitro and in vivo genotoxicity
Substantial in vitro and in vivo data has been generated and sup-
port the absence of genotoxicity potential of LBG. The initial JECFA
evaluation considered several in vitro genotoxicity studies per-
formed using Saccharomyces cerevisiae and Salmonella typhimurium
(strains TA1535, TA1537 and TA1538). Those in vitro genotoxicity
tests were performed in the absence and presence of metabolic
activation from adult mouse (ICR), rat (Sprague–Dawley) and mon-
key (Macaca mulatta). The overall studies did not provide evidence
for genotoxicity under the conditions tested which led the JECFA to
conclude that LBG is not genotoxic in vitro. Maxwell and Newell
(1972) reported that negative results were obtained for LBG in an
in vitro bacterial gene mutation test and an in vitro chromosome
aberration test. Finally, the genotoxicity tests performed by Green
and Ziegler in the context of NTP testing programs further argue for
the absence of in vitro genotoxic potential of LBG (Green, 1977;
Zeiger et al., 1992). Indeed, no evidence of in vitro genotoxicity
was found based on various Ames tests using S. cerevisiae (D-3)
and S. typhimurium (TA11530 and G46) in the absence of metabolic
activation (Green, 1977). In addition, the Ames test performed for
LBG in the presence and absence of liver S9 fraction preparation
from male Sprague–Dawley rats and male Syrian hamsters (S.
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TA1537 and TA1538) gave all negative results (Zeiger et al., 1992).
Maxwell and Newell (1972) performed three in vivomutagenic-
ity tests using LBG, which included a host-mediated microbial test,
a chromosome aberration test and a dominant lethal test. In all
tests, rats were treated with undeﬁned quantities of LBG (i.e. max-
imum tolerated, intermediate or low dose). The authors indicated
that all tests gave negative results for LBG. The available studies
uniformly demonstrate negative results both in in vitro and
in vivo mutagenicity tests. It should nevertheless be underlined
that due to its negligible hydrolysis in the gastrointestinal tract,
LBG is not expected to become systemically available. Therefore,
some of the in vivo tests conducted might not be relevant since
the test substance did not come into contact with the target cells.
4.8. Carcinogenicity
All the available studies indicate that locust bean gum (LBG) is
not carcinogenic. In the JECFA toxicological monograph on LBG, ref-
erence is made to the chronic/carcinogenicity study completed by
Carlson and Domanski (1980). As depicted in the paragraphs
above, rats of both sexes (Fisher 344) were exposed to 0, 25,000
or 50,000 ppm LBG in the diet (equivalent to 0, 1250 or 2500 mg/
kg bw/day, respectively) for a period of 103 weeks. In addition,
50 male and 50 female Charles River albino rats received a 5% alpha
cellulose containing diet (control) or a diet supplemented with 2 or
5% LBG (equal to 1000 and 2500 mg/kg bw/day) for a period of
24 months. No gross or microscopic lesions were reported follow-
ing LBG treatment neither in Fisher 344 rats nor in Charles River
rats.
As depicted above, for the chronic feeding study/carcinogenicity
NTP study, the F344 rats or B6C3F1 mice were fed a diet containing
LBG at 0, 2.5 or 5.0% (equal to 0, 1250 or 2500 mg/kg bw/day in rats
and 0, 3750 or 7500 mg/kg bw/day) for a period of 103 consecutive
weeks (Melnick et al., 1983; NTP, 1986). Some increased tumor
incidence in different tissues of rats and mice were reported. In
fact, it was reported that alveolar/bronchial adenomas were found
in male mice at the intermediate dose of 3750 mg LBG/kg bw/day
and cortical adenomas in the adrenal gland of female rats were
found following exposure to 1250 and 2500 mg LBG/kg bw/day.
According to the publication of Melnick, tumours commonly
observed in ageing F344 and rats and B6C3F1 mice were seen in
both control and dosed animals and none were considered to be
related to the administration of LBG. The peer reviewed NTP report
conﬁrmed that these increased tumor incidences, were marginally
signiﬁcant and/or non-dose related and/or within the range of his-
torical controls and/or only observed in one sex of the species. It
was also indicated that the rats and mice might have tolerated
higher dosages than 5% in the diet, but this was the maximal dos-
age recommended for chronic feeding studies. This absence of a
carcinogenic effect is conﬁrmed by the data of the other galacto-
mannan containing gums (i.e. guar gum and tara gum) that were
shown not to be carcinogenic when fed to mice and rats.
In conclusion, the preclinical safety data on LBG taken together
demonstrate no reproducible evidence for LBG-related adverse
effects on mortality, general condition and food intake of the ani-
mals. Locust bean gum did also not promote detrimental effects
on reproduction and did not exert a teratogenic effect. Finally,
the compound was not genotoxic or mutagenic, neither did its die-
tary exposure result in carcinogenesis. From the available data, a
range of No Observed Adverse Effect Levels (NOAELs) from the
selected studies conducted with at least 2 dose levels in animal
studies can be determined to range from 2500 to 12,000 mg/
kg bw/d in the rats and from 7500 to 20,000 mg/kg bw/day in the
mice (Table 2). In all key and good quality studies identiﬁed, the
NOAEL was determined to be at the highest dose administered inthe diet. Notably, the highest LBG dose level tested in chronic feed-
ing and carcinogenicity studies was at 5% in order not to promote
nutritional imbalance, this is in compliance with Guidelines for
Carcinogen Bioassay but also with more recent OECD guidelines
453 (OCDE, 2009; Sontag et al., 1976). Nevertheless, in view of
the toxicity proﬁle and chemical properties of LBG it can be
assumed that even higher dose levels (well above 5% in the diet)
might also have been well tolerated by the animals without LBG-
speciﬁc adverse effects. This implies that the NOAEL for chronic
toxicity and carcinogenicity could also be higher.5. Paediatric tolerance and safety
As indicated earlier, since LBG is not systemically available, the
only site of contact within a human body is in the gut. In this
respect, tolerance is considered as one of the main critical param-
eters to capture potential issues in humans and, especially in the
target population itself to capture organ immaturity. Therefore,
the existing data on LBG in the paediatric context is of strong
added value to the already existing package.5.1. History of safe use
LBG has an extensive history of use as a food additive in general
but also in various drug formulations. With respect to the speciﬁc
group consisting of neonates and young infants, it should be men-
tioned that as early as in the 50’s, some investigators studied the
potential beneﬁcial effect of locust bean derived indigestible poly-
saccharides on infant diarrhoea or vomiting without reported
untoward effects (Beynon, 1949; Rivier, 1952). Furthermore, the
ﬁrst published investigations and trials conducted either with
LBG as a thickener or as commercialized LBG-thickened formula
dates back more than 20 years ago (Greally et al., 1992;
Vandenplas et al., 1994). Since that time, LBG-thickened formula
has been continuously present on the market and given to an
extensive number of infants to treat regurgitation without
reported safety concern.
From the clinical practice and according to paediatric societies’
recommendations, the use of LBG-thickened formulas should be
exercised only in healthy term infants with uncomplicated GER
and be excluded in premature infants and low birth weight infants
(Birch and Newell, 2009; Vandenplas et al., 2009). Isolated cases
have been reported of prematures or low birth weight infants with
GERD, fed infant formulas thickened with LBG experiencing severe
adverse effects or fatality. This was hypothesized mainly to be due
to the very immature state of their gastrointestinal tract. In
response to a position of the ESPGHAN (European Society of Paedi-
atric Gastroenterology, Hepatology and Nutrition) on management
of GER, Sievers and Schaub (2003) mention a study from 1990 in
which 6 premature infants were fed 0.2–0.5 g/100 mL LBG formula
to reduce vomiting, resulting in an increased frequency of defeca-
tion, metabolic acidosis and hypokalemia as long as the exposure
continued. It is hypothesized by the authors that an increased loss
of bicarbonate and potassium may be caused by the increased fre-
quency of defecation due to a shortened gastrointestinal passage
time or binding of potassium to the LBG component. Clarke and
Robinson (2004) expressed their concern regarding induction of
fatal necrotizing enterocolitis observed in 2 cases in which extre-
mely low birth weight premature infants were fed LBG thickened
milk. According to Clarke, thickened feeds may have led to necro-
tising enterocolitis as a result of bowel obstruction with subse-
quent bacterial overgrowth or following direct mucosal injury by
caloriﬁc dense milk. However, the pathophysiology of these 2 cases
was not investigated.
Table 2
No Observed Adverse Effect Levels (NOAELs) for LBG identiﬁed in sub-acute, sub-chronic, chronic and carcinogenicity studies conducted with at least 2 dose levels.
Reference Species (strain) Type of study NOAEL (mg/kg bw/day)
NTP (1982) Rat (Fisher 344) Sub-acute, 14 days 12000a
NTP (1982) Mice (B6C3F1) Sub-acute, 14 days 20000a
Til et al. (1974) Rat Sub-chronic, 13 weeks 4500a
NTP (1982) Rat (Fisher 344) Sub-chronic, 13 weeks 9000a
NTP (1982) Mice (B6C3F1) Sub-chronic, 13 weeks 20000a
Carlson and Domanski (1980) Rat (Fisher 344), Rat (Charles River Albino) Chronic, 103 weeks 2500a
NTP (1982), Melnick et al. (1983) Rat (Fisher 344) Chronic/carcinogenicity, 103 weeks 2500a
NTP (1982), Melnick et al. (1983) Mice (B6C3F1) Chronic/carcinogenicity, 103 weeks 7500a
a NOAEL identiﬁed at the highest dose tested.
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Several paediatric studies investigating the beneﬁcial effect of
LBG on regurgitation included infants below or above the age of
12 weeks have been published (Borrelli et al., 1997; Hegar et al.,
2008; Herrewegh, 2000; Iacono et al., 2002; Levtchenko et al.,
1998; Marinova and Stoimenova, 1999; Miyazawa et al., 2007,
2004, 2006; Vandenplas et al., 1994, 2013; Vivatvakin and
Buachum, 2003; Wenzl et al., 2003) (reviewed in Table 3). The
investigations were not primarily conducted to address safety
but remain of critical importance in capturing potential tolerance
and any general toxicity issues, as it can be assumed that in case
of moderate to severe adverse outcomes ruling out the innocuous
nature of LBG, this would have been obviously mentioned by the
investigators. In those trials, LBG was either provided in the form
of commercial LBG-thickened formulas or in the form of standard
formula to which LBG was added by the investigators. All the stud-
ies taken together, about 400 infants among which most of them
were included at an age below 12 weeks, were administered
LBG-thickened formulas with LBG dosages ranging from 0.35 to
0.6 g/100 mL (covering the main target level of 0.5 g/100 mL) with
treatment durations of 1 week to 2 months (Table 3). The overall
results from those studies does not point at any speciﬁc safety con-
cern in healthy infants aged below or above 12 weeks as the
authors did not report any adverse effects in the exposed infants.
In all studies, the thickener exerted a clear positive effect on symp-
toms of regurgitation, without negatively impacting feedings and
growth (weight and height gain). Furthermore, in the investiga-
tions the LBG-thickened formulas were reported to be well toler-
ated (i.e. no negative effect of the test substance on vomiting, no
change in stools consistency and frequency). The same type of con-
clusions on tolerance were noted in the systematic review that
looked for the effects of various thickened feeds on gastro-oesoph-
ageal reﬂux in infants including LBG-thickened formulas (Horvath
et al., 2008).5.3. Hypersensitivities
Only one case-report of allergy to LBG when included in thick-
ened infant formula was reported. None of the intervention studies
cited above did report any hypersensitivity or allergy to LBG.
Savino et al. (1999) reported a case of allergy to LBG in a 5 month
old child upon a single feeding with a LBG-thickened infant for-
mula, resulting in explosive vomiting, urticaria and a rash on her
face. A ﬂuorescent allergosorbent test was negative for milk, a-
lactalbumin, b-lactoglobulin, casein, soy, peanuts, barley, cod,
and egg white but was positive for egg yolk. At 8 months a chal-
lenge with milk formula containing LBG induced urticaria and
vomiting occurred within 30 min of exposure, related by the
authors to LBG induced allergy. Some investigations have sug-
gested that heat-processed locust bean gum no longer promoted
allergic reaction in allergic children (Fiocchi et al., 1999). Onlyone isolated adult case report of LBG-hypersensitivity has been
published following oral exposure (Alarcon et al., 2011). Altogether
this indicates that the prevalence of LBG-hypersensitivity after
ingestion is expected to be very low in the overall population.6. Nutritional effects
6.1. Impact on mineral absorption
Mainly in vitro studies have suggested that LBG could negatively
modify the absorption efﬁciency of some minerals. In different
experiments using an in vitro continuous-ﬂow dialysis system with
a preliminary intraluminal digestive phase, Bosscher evaluated the
availability of calcium, iron and zinc related to the presence of
digestible and indigestible carbohydrates as thickening agent in
infant formula (Bosscher et al., 2001, 2003, 2000). The studies were
optimised to simulate the conditions of infants aged less than
6 months and children aged 6 months and older (Bosscher et al.,
2000). Absorption was tested using samples with low and high
mineral content, prepared with formula containing no thickening
agent or 0.4 g/100 mL (Bosscher et al., 2003, 2000) and formula
containing several concentrations of LBG in a range of 0.42–
1.44 g/100 mL in casein-based formula and 0.14–1.44 g/100 mL in
whey-based formula (Bosscher et al., 2001). It was found that,
compared to the non-thickened infant formulas and under the
in vitro conditions used, the availability of calcium, iron, and zinc
could be decreased in products thickened with locust bean gum
(Bosscher et al., 2001, 2000). A dose related tendency to a decrease
in bioavailability of the respective minerals was found, although in
the context of a whey-based formula thickened with lower concen-
trations of LBG (0.14–0.42 g/100 mL) the availability of elements
was found to be in the same range as the control formula without
thickener (Bosscher et al., 2001). In addition, the decreased mineral
availability in presence of LBG was also reported not to be statisti-
cally signiﬁcant in all the investigations and for all LBG-thickened
formulas tested (Bosscher et al., 2003, 2000). The potential effect
on mineral availability was not unique to LBG and also observed
with other ﬁbres like oligofructose, maltodextrin and high-esteri-
ﬁed pectin (Bosscher et al., 2003). Comparable observations have
been made in more recent in vitro experiments where LBG was
added to standard infant formula and then submitted to in vitro
enzymatic digestion (González-Bermúdez et al., 2014). The com-
parison was made with digestible thickening agents modiﬁed corn
and rice starch. The authors observed a potential decrease of solu-
bility and dialyzability for calcium, iron and zinc at LBG levels
above 0.5 g/100 mL and 1 g/100 mL, whereas for the other thicken-
ers only affected Ca.
Harmuth-Hoene and Schelenz (1980) conducted a short term
in vivo study in weanling rats with locust bean gum and the other
ﬁbres guar gum, sodium alginate, agar–agar and carrageenan
(8 days, 12 rats per group). Their data suggested that a very high
dosage up to 10% LBG in the diet could interfere with the
Table 3
Summary of infant paediatric studies with tolerance and safety related information.
Reference Study details Study endpoints Study outcomes (impact of LBG)
Paediatric studies including infants <12 weeks (with tolerance and safety parameters)
Vandenplas et al.
(2013)
Subjects: 115 term infants, age: 2 weeks–5 months (mean age
9.1 weeks at inclusion),
Study design: prospective, double blind, randomized cross over trial
(without wash out period)
Duration of trial: 1 month
Study groups: ﬁrst group of infants receive LBG-thickened formula (Gal-
lia AR, LBG 0.4 g/100 mL) for 2 weeks followed by LBG + starch-thick-
ened formula (Novalac AR Digest, LBG 0.45 g/100 mL + 0.32 g/100 mL
starch) for 2 weeks, other group of infants fed in the reverse order
Growth: body weight and weight gain
Intake volume of formula
Number of regurgitation & regurgitation vol-
ume
Stool characteristics
No negative impact on weight and length
No speciﬁc effect on formula intake
Good tolerance of both formulas
Both formulas did have a clear beneﬁcial effect on diminishing
regurgitation (frequency, volume)
No difference in stool frequency and consistency
Number of adverse events reported to be low in both groups
Levtchenko et al.
(1998)
Subjects: 40 term infants, age: 1 week
Study design: open randomized controlled parallel groups trial
Duration of trial: 3 months
Study groups: control group received standard formula (Nutrilon Pre-
mium, casein/whey ratio 40%/60%) (n = 20) and test group received a
LBG-thickened formula (Nutrilon AR, LBG 0.4 g/100 mL, casein/whey
ratio 80%/20%) (n = 20)
Growth: height and weight
Intake volume of formula
Blood sampling (iron, iron binding capacity,
urea, calcium, phosphorus, protein, albumin,
prealbumin, zinc)
No negative effect on growth
Higher formula intake in the group receiving LBG-thickened for-
mula, leading to higher protein intake associated with increased
plasmatic urea but lower albumin due to the lower nutritional
value of casein.
Nutritional blood parameters remained in the normal range,
except for zinc levels that was below the normal range but compa-
rable in both groups.
No speciﬁc adverse effects reported by the authors
Vivatvakin and
Buachum
(2003)
Subjects: 20 term Thai infants, age 4–24 weeks (mean age 13.4 weeks)
Study design: open, randomized controlled cross over trial
Duration of trial: 2–4 weeks
Study groups: infants ﬁrst for 2 weeks under standard formula, then for
2–4 weeks with LBG-thickened formula (LBG 0.6 g/100 mL, manufactur-
ers information)
Growth: weight gain
Gastric emptying time
Frequency regurgitation and vomiting
No negative impact on weight gain
Improved tolerance (diminished frequency regurgitation and
vomiting)
No effect on colic symptoms, non-signiﬁcant decrease in stool fre-
quency and signiﬁcant increase in ﬂatus
No signiﬁcant effect on gastric emptying half time
Authors conclude that the milk thickening agent can be safely
administered to young infants
Miyazawa et al.
(2007)
Subjects: 20 term infants, age: <8 weeks (mean age 5.1 weeks)
Study design: randomized controlled cross over trial (without wash out
period)
Duration of trial: 1 week
Study groups: ﬁrst group of infants receiving standard formula for
1 week (HL-00) and then receiving the LBG-thickened formula for 1
week (HL-350, LBG 0.35 g/100 mL), other group of infant fed in the
reverse order
Growth: weight gain
Intake volume of formula and feeding
time
Frequency regurgitation and vomiting
Gastric emptying
Number of bowel movements
Blood chemistry parameters (glucose, insulin
and triglycerides)
No negative impact on weight gain
No effect on formula intake (volume and duration)
Decreased regurgitation
No signiﬁcant effect on gastric emptying half time
Slight signiﬁcant increase in bowel movement
Decreased plasma glucose, insulin and triglycerides (beneﬁcial
effect as stated by the authors)
No speciﬁc adverse effects reported by the authors
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Iacono et al.
(2002)
Subjects: 166 term infants, age: <16 weeks (median age 6 weeks)
Study design: randomized, controlled parallel groups trial
Duration of trial: 8 weeks
Study groups: control group (n = 82) receiving standard formula
(Humana Plus), treated group (n = 84) receiving LBG-thickened formula
(Humana AR, LBG level not mentioned)
Growth: height/weight ratios
Frequency of regurgitation
No impact on growth
Signiﬁcant effect with decreased regurgitation
Some infants experiencing diarrhoea in LBG group (14 out 84
infants)
No speciﬁc adverse effects reported by the authors
Hegar et al. (2008) Subjects: 60 term infants, age: 4–12 weeks (median age 6 weeks)
Study design: randomized, controlled parallel groups trial
Duration of trial: 4 weeks
Study groups: standard infant formula (group A, n = 20), 5 g of rice cer-
eal added to 100 mL standard formula (group B, n = 20) and LBG-thick-
ened formula (Nutrilon AR1, LBG 0.4 g/100 mL) (group C, n = 20)
Growth: weight gain
Intake volume of formula
Tolerance and stool characteristics (fre-
quency and consistency)
No negative impact on weight gain
Natural decrease of regurgitation and vomiting in all 3 groups but
even more marked in the LBG group (3-fold decrease) although
not statistically signiﬁcant due to the low number of subjects
No effect on stool characteristics
No speciﬁc adverse effects reported by the authors
Marinova and
Stoimenova
(1999)
Subjects: 15 infants, age: 4–20 weeks
Study design: controlled cross over
Duration of trial: 10–14 days
Study group: infants previously under standard formula were fed with
LBG-thickened formula LBG 0.6 g/100 mL
Growth: weight gain
Reﬂux index and reﬂux episodes
Frequency of vomiting
No negative impact on weight gain
Signiﬁcant decrease in the number and duration of regurgitation
episodes
Decreased vomiting
No speciﬁc adverse effects reported by the authors
Herrewegh (2000) Subjects: infants, from birth
Study design: open, controlled parallel groups trial
Duration of trial: 2 weeks
Study group: infants initially receiving standard formula (Frisolac) for 2
weeks then receive either the standard formula or a LBG-thickened for-
mula (Frisovom, LBG 0.6 g/100 mL)
Effect on bacterial ﬂora in faeces Stimulates growth of beneﬁcial lactobacillus and streptococcus,
inhibits the growth of enterococcus
No speciﬁc adverse effects reported
Vandenplas et al.
(1994)
Subjects: 20 term infants, age: 1–16 weeks
Study design: double blind randomized, controlled parallel groups trial
Duration of trial: 1 week
Study group: infants receiving control commercial formulas (n = 10)
and infants receiving the same formulas thickened with LBG (LBG
0.4 g/100 mL) (n = 10)
Regurgitation parameters: number, esopha-
geal pH monitoring, number of reﬂux
episodes
Decreased number of regurgitation and reﬂux index
No speciﬁc adverse effects reported by the authors
Wenzl et al. (2003) Subjects: 14 infants, age: mean age 6 weeks
Study design: randomized double blind controlled cross over trial
Duration of trial: 24 h or 6 feedings
Study group: infants randomly assigned to alternatively receive either a
LBG-thickened formula (formula A, LBG 0.4 g/100 mL) or a standard for-
mula (formula B)
Regurgitation score (frequency and
volume)
Other reﬂux parameters
Signiﬁcant decrease of regurgitation frequency and amount
(score)
Reduction in non-acid regurgitation episodes
The authors reported no dropouts during the study
No speciﬁc adverse effects reported
(continued on next page)
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Table 3 (continued)
Reference Study details Study endpoints Study outcomes (impact of LBG)
Paediatric studies including infants <12 weeks (with tolerance and safety parameters)
Vandenplas et al.
(2013)
Subjects: 115 term infants, age: 2 weeks–5 months (mean age
9.1 weeks at inclusion),
Study design: prospective, double blind, randomized cross over trial
(without wash out period)
Duration of trial: 1 month
Study groups: ﬁrst group of infants receive LBG-thickened formula (Gal-
lia AR, LBG 0.4 g/100 mL) for 2 weeks followed by LBG + starch-thick-
ened formula (Novalac AR Digest, LBG 0.45 g/100 mL + 0.32 g/100 mL
starch) for 2 weeks, other group of infants fed in the reverse order
Growth: body weight and weight gain
Intake volume of formula
Number of regurgitation & regurgitation vol-
ume
Stool characteristics
No negative impact on weight and length
No speciﬁc effect on formula intake
Good tolerance of both formulas
Both formulas did have a clear beneﬁcial effect on diminishing
regurgitation (frequency, volume)
No difference in stool frequency and consistency
Number of adverse events reported to be low in both groups
Levtchenko et al.
(1998)
Subjects: 40 term infants, age: 1 week
Study design: open randomized controlled parallel groups trial
Duration of trial: 3 months
Study groups: control group received standard formula (Nutrilon Pre-
mium, casein/whey ratio 40%/60%) (n = 20) and test group received a
LBG-thickened formula (Nutrilon AR, LBG 0.4 g/100 mL, casein/whey
ratio 80%/20%) (n = 20)
Growth: height and weight
Intake volume of formula
Blood sampling (iron, iron binding capacity,
urea, calcium, phosphorus, protein, albumin,
prealbumin, zinc)
No negative effect on growth
Higher formula intake in the group receiving LBG-thickened for-
mula, leading to higher protein intake associated with increased
plasmatic urea but lower albumin due to the lower nutritional
value of casein.
Nutritional blood parameters remained in the normal range,
except for zinc levels that was below the normal range but compa-
rable in both groups.
No speciﬁc adverse effects reported by the authors
Vivatvakin and
Buachum
(2003)
Subjects: 20 term Thai infants, age 4–24 weeks (mean age 13.4 weeks)
Study design: open, randomized controlled cross over trial
Duration of trial: 2–4 weeks
Study groups: infants ﬁrst for 2 weeks under standard formula, then for
2–4 weeks with LBG-thickened formula (LBG 0.6 g/100 mL, manufactur-
ers information)
Growth: weight gain
Gastric emptying time
Frequency regurgitation and vomiting
No negative impact on weight gain
Improved tolerance (diminished frequency regurgitation and
vomiting)
No effect on colic symptoms, non-signiﬁcant decrease in stool fre-
quency and signiﬁcant increase in ﬂatus
No signiﬁcant effect on gastric emptying half time
Authors conclude that the milk thickening agent can be safely
administered to young infants
Miyazawa et al.
(2007)
Subjects: 20 term infants, age: <8 weeks (mean age 5.1 weeks)
Study design: randomized controlled cross over trial (without wash out
period)
Duration of trial: 1 week
Study groups: ﬁrst group of infants receiving standard formula for
1 week (HL-00) and then receiving the LBG-thickened formula for 1
week (HL-350, LBG 0.35 g/100 mL), other group of infant fed in the
reverse order
Growth: weight gain
Intake volume of formula and feeding
time
Frequency regurgitation and vomiting
Gastric emptying
Number of bowel movements
Blood chemistry parameters (glucose, insulin
and triglycerides)
No negative impact on weight gain
No effect on formula intake (volume and duration)
Decreased regurgitation
No signiﬁcant effect on gastric emptying half time
Slight signiﬁcant increase in bowel movement
Decreased plasma glucose, insulin and triglycerides (beneﬁcial
effect as stated by the authors)
No speciﬁc adverse effects reported by the authors
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Pediatric studies including infants >12 weeks (with tolerance and safety parameters)
Borrelli et al.
(1997)
Subjects: 24 infants, age: 5–11 months (median age: 8 months)
Study design: double blind randomized controlled parallel groups
trial
Duration of trial: 2 weeks
Study groups: infants receiving either a standard formula (n = 12) or
LBG-thickened formula (Nutrilon AR, 0.4 g/100 mL) (n = 12)
Caloric intake
Frequency of regurgitation
Symptomatic scoring of GOR: frequency of
regurgitation and/or vomiting, irritability
and sleep disturbances, caloric intake, paren-
tal discomfort
Signiﬁcant and more pronounced reduction in score of symptoms
and frequency of GOR, signiﬁcant reduction in number of episodes
of emesis
No speciﬁc adverse effects reported by the authors
Miyazawa et al.
(2004)
Subjects: 30 infants, age: 5–11 months (median age: 8 months)
Study design: randomized controlled cross over groups trial
Duration of trial: 1 week
Study groups: in a cross over fashion infants in group A (n = 16) received
either standard formula (HL-00) or LBG-thickened formula (HL-450,
LBG 0.45 g/100 mL), similarly infants in group B (n = 14) received either
standard formula or LBG-thickened formula (HL-350, LBG 0.35 g/
100 mL)
Growth: weight gain
Intake volume of formula
Number of regurgitation
Number of bowel movements
No negative effect on weight gain during the study (and at 7 &
12 months of age)
No effect on formula intake
All infants had less regurgitation when fed LBG-thickened formula
No negative effect on bowel movement (either no effect in HL-450
group or slight higher number of bowel movements in HL-350
group)
The authors reported no serious adverse events linked to the LBG
and that no infants had any complication during the study
Miyazawa et al.
(2006)
Subjects: 27 infants, age: 4.5–4.75 months
Study design: randomized controlled parallel groups trial
Duration of trial: 1 week
Study groups: in a cross over fashion infants one group (n = 13) received
either standard formula (HL-00) or LBG-thickened formula (HL-350,
LBG 0.35 g/100 mL), similarly infants in a second group (n = 14)
received either standard formula or LBG-thickened formula (HL-450,
LBG 0.45 g/100 mL)
Growth: weight gain
Intake volume of formula
Number and volume of regurgitation
Number of bowel movements
Signiﬁcant decrease in the number of regurgitation, no effect on
regurgitation volume
2/13 infants and 1/14 infants when under LBG 0.35 g/100 ml and
0.45 g/100 mL were reported to have increased bowel movement
but not associated with severe diarrhea
The authors reported no complications/adverse effects after feed-
ing with LBG-thickened formula
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Table 4
Formula intake, estimated intake of LBG and calculated Margins of Safety.
Infant age (weeks) Weight (kg)a Formula intake (mL per day)b LBG intakec (g per day) LBG intakec (mg per kg bw per day) Margin of Safety
Rat NOAEL Mice NOAEL
3 3.95 615 2.96 750 12 27
6 4.75 712.5 3.56
12 5.95 892.5 4.46
a Average of median body weight for boys and girls infants according to WHO Child Growth Standards.
b Formula intakes based on WHO recommendations of 150 mL per kg bw per day.
c A typical LBG level of 0.5 g/100 mL is considered.
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ance of intake and excretion. It should be stressed that in that ani-
mal study this type of effect was not exclusive to LBG and was also
observed for other ﬁbres at the same level in the diet (10%). Con-
trary to the data obtained in vitro in the Bosscher studies, LBG
did not affect calcium and iron absorption and was among the
ﬁbres less inhibiting mineral absorption.
An open randomized prospective study of Levtchenko et al.
(1998) addressed the aspect of intestinal mineral and other nutri-
ents’ bioavailability with infant formula containing 0.4 g/100 mL
LBG. The groups (n = 20) received either a regular adapted or a
LBG-thickened formula from birth to 13 weeks of age. All infants
grew normally. All serum parameters including those related to
minerals where comparable between the control and test groups
when evaluated at 13 weeks of age, and most were within the nor-
mal range (iron, iron binding capacity, calcium, phosphorus, pro-
tein, prealbumin and zinc). An increased plasma urea level as a
result of higher ingestion of formula and, a lower serum albumin
level due to the lower nutritional value of casein versus whey,
were found in the group receiving the LBG-thickened formula;
both parameters were still in the normal clinical range.
In summary, in vitro investigations and one animal diet study
suggest that the addition of LBG in foods might decrease the bio-
availability of some minerals. The clinical relevance of this
in vitro data generated without the complete formulation of mar-
keted thickened infant formula remains uncertain. Indeed, it
should be underlined that a lack of consistency exists on the spe-
ciﬁc minerals that could potentially be affected between the
in vitro and animal in vivo results. Furthermore, the potential
impact on mineral absorption observed at the higher range of die-
tary ﬁbre level is not a feature unique to LBG as this has been com-
monly reported for a range of other ﬁbre compounds. Of utmost
importance, no adverse effect on the nutritional status and growth
of infants could be observed when administered a LBG-thickened
formula. This was also highlighted in the joint European and North
American Societies for Paediatric Gastroenterology Hepatology and
Nutrition (ESPGHAN–NASPGHAN) guidelines for management of
infant anti-regurgitation, stating that the available evidences in
the paediatric context indicate both normal growth and normal
nutritional parameters when fed thickened formula (Vandenplas
et al., 2009). Finally, a global review of mineral composition of
standard infant formula available on the market compared to their
equivalent thickened with LBG generally showed higher mineral
content per 100 mL of ready to use product (i.e. calcium, phospho-
rus, potassium, iron, zinc, copper) allowing to compensate for any
minor or moderate diminished mineral or trace element
bioavailability.
6.2. Other nutritional effects
Animal studies conducted with high end LBG dosage indicated a
trend to lower blood lipid levels and an effect on ﬂattening glucose
peaks. Evans et al. (1992) investigated the effect of LBG on choles-
terol metabolism in adult male Wistar rats. Rats were given a basaldiet free from ﬁbre, a diet containing puriﬁed cellulose or a diet
containing LBG (80 g LBG/kg diet, equal to 9600 mg/kg bw/day).
Rats were dosed for 2 weeks. The rate of hepatic total lipid and
cholesterol synthesis was signiﬁcantly decreased when compared
to controls; the hepatic lipid accumulation, liver and serum choles-
terol (i.e. non-HDL cholesterol) levels were signiﬁcantly lower in
the LBG group. Similar observations were made in the work by
Ershoff et al. (1962) in which adult male Holtzman rats were
exposed to a basal diet containing 1% cholesterol or a diet contain-
ing 1% cholesterol and a unique dose of 10% LBG (equal to
12,000 mg/kg bw/day, respectively) for 28 days. It should be noted
that such deviations in cholesterol was in all cases observed in
short-term studies were only a single high dose of LBG (around
10% in diet) was tested but not reported in longer term 90-days
toxicity studies with increasing doses tested. This type of varia-
tions in cholesterol levels is also reported for other ﬁbres com-
pounds at high doses in animal studies but without consistent
dose–response relationships (i.e. other galactomannans gums,
fructo-oligosaccharides) (Beylot, 2005; Coulet et al., 2014, 2013;
Evans et al., 1992). In adulthood this might be perceived as a posi-
tive effect on lipid status. During early life phases this might not be
seen as a beneﬁt, although the relevance also in the paediatric clin-
ical practice of such effect is uncertain given the very large margin
between the actual use-levels in thickened infant formula and the
single high dose that were tested in animals.
Tsai and Peng (1981) demonstrated a ﬂattening of the post
prandial serum glucose response in adult male Sprague–Dawley
rats when ingesting LBG. Results revealed that LBG inﬂuenced
serum glucose concentrations following the oral co-exposure to a
glucose solution and 1.0, 1.5, or 2.5% (w/v) LBG. In general, a
dose-dependent decrease in glucose serum concentration and a
decrease in the subsequent rebound to hypoglycaemia after dosing
were observed. Conversely, the oral exposure to LBG did not alter
serum glucose concentrations following intravenous glucose infu-
sion suggesting that this effect might occur during digestive phases
prior to absorption. The authors indicated that LBG was also found
to affect the rate of gastric emptying under the conditions used
which might also have a positive effect on glucose response in ani-
mals. This ﬂattening effect on glucose response in preclinical ani-
mal studies is not unique to LBG and has often been reported in
short term studies for other galactomannan-containing ﬁbre com-
pounds such as guar gum or for other ﬁbre compounds (Garthoff
et al., 2010; Prieto et al., 2006).
A study of Harmuth-Hoene and Schwerdtfeger (1979) is
referred to in the JECFA toxicological monograph on LBG. The pro-
tein digestibility in weanling rats as a result of LBG in the animal
feed was evaluated. Weanling Sprague–Dawley rats were fed 10%
LBG in the diet, and showed a signiﬁcant rise in faecal nitrogen
loss, reportedly resulting in a reduction of apparent protein digest-
ibility (75% in LBG, 87.8% in control). Furthermore, the faecal dry
matter was signiﬁcantly increased in the 10% LBG group. The rele-
vance of the observed effects, more related to the substantial
increase in viscosity of feed observed as result of the addition of
LBG at high levels 10% addition to the animal diet, is however ques-
L. Meunier et al. / Regulatory Toxicology and Pharmacology 70 (2014) 155–169 167tionable in the context of infants ingesting liquid formula where
LBG levels fall in the very low range of 0.5 g/100 mL (0.5%); indeed
no negative effect on protein absorption could be observed in the
previously mentioned clinical study of Levtchenko et al. (1998) at
typical clinical use-level.
7. Integrated safety evaluation and conclusion
The safety of LBG has been well established with a wide range of
conventional toxicological studies covering all major endpoints,
including short-term toxicity, long-term toxicity, carcinogenicity,
reprotoxicity, teratogenicity, and genotoxicity. In all animal stud-
ies, conducted in different species, reproducible adverse effects
could not be observed. Although all these investigations are not
of recent date, the key studies cited were actually designed and
conducted to cover most important parameters recommended in
harmonized guidelines for testing of chemicals (OECD, FDA). In
addition, the NOAELs obtained from these investigations were sys-
tematically retrieved at the highest dose tested. It is therefore quite
plausible that higher dosages would have also been tolerated with-
out LBG-speciﬁc associated adverse effects in the long-term stud-
ies. Available metabolism and digestibility studies indicate that
LBG is not expected to be hydrolysed and will therefore not be
absorbed to a signiﬁcant degree in the human neonatal intestine,
resulting in mainly unchanged excretion in the faeces. Even if lim-
ited hydrolysis occurs, which is theoretically possible, the resulting
degradation products are known as normal physiological constitu-
ents of known oligosaccharides and monosaccharides of mannose
and galactose that could enter basic metabolic pathways of the
neonate. A small proportion of LBG is demonstrated to be fer-
mented by the intestinal microbiota leading to the formation of
chemical entities like short-chain fatty acids that are common to
fermented ﬁbres.
Due to the intrinsic biochemical nature of LBG (an indigestible
carbohydrate), the absence of a characterized toxicity endpoint of
departure based on animal studies and paediatric data as summa-
rized in Table 3, it is considered adequate to use the Margin of
Safety (MoS) approach for the purpose of the safety evaluation.
This approach has been already advocated for other ﬁbres or
ﬁbres-like compounds (i.e. alpha-cyclodextrin) in ofﬁcial expert
safety evaluations (EFSA, 2007; JECFA, 2006). The No Observed
Adverse Effect Levels (NOAELs) identiﬁed in studies of sufﬁcient
quality and duration (sub-chronic and chronic) were systemati-
cally at the highest dose tested and, as stated above, it can be
assumed that in chronic toxicity studies higher dosages could have
been tolerated without LBG-speciﬁc adverse effects. This justiﬁes
referring to the NOAELs from sub-chronic toxicity studies address-
ing the highest dose tested in repeated dose toxicity studies of suf-
ﬁcient duration. The NOAELs for sub-chronic toxicity studies were
9000 mg/kg bw/day in the rat and up to 20,000 mg/kg bw/day in
the mice, respectively.
WHO recommends a typical ﬂuid intake (human milk or infant
formula) of 150 mL/kg bw/day in term infants (WHO, 2009).
Assuming a typical LBG use-level of 0.5 g/100 mL the resulting
exposure to would be of 0.75 mg/kg bw/day (750 mg/kg bw/day).
By comparing the estimated intake (750 mg/kg bw/day) with the
NOAELs cited above (9000 and 20,000 mg/kg bw/day), a MoS can
be determined to be around 12–27, depending on whether the
NOAEL from the rat or the mice studies are considered (Table 4).
In view of the safety proﬁle of LBG and based on all the arguments
evocated above for LBG, more particularly since the thickener has
negligible systemic bioavailability and is, by way of consequence,
not expected to cause adverse systemic effects, or be subject to
metabolism nor anticipated to inﬂuence the metabolism in an
immature body, such MoS is considered adequately protective for
the target population consisting of healthy neonates and younginfants. Furthermore, the magnitude of this MoS falls in the same
range as other calculated MoS for well-known ﬁbre compounds
either used as nutritional substances in infant formula such as
fructo-oligo saccharides (FOS; as calculated by Coulet et al.
(2013)) or as thickening agents such as alpha-cyclodextrin (EFSA,
2007; JECFA, 2006).
To further substantiate the MoS of LBG derived from animal
experiments, the ﬁndings obtained from human intervention
studies are crucial. It can be emphasized that LBG has a history
of safe use of more than 20 years in thickened infant formulas
or foods for infants and young children sold on the market; LBG
was shown to be well tolerated and was not associated with overt
adverse effects in paediatric trials where LBG was included in
anti-regurgitating formulas at levels of 0.35 up to 0.6 g/100 mL
in term infants aged below or above 12 weeks. Isolated reports
mention adverse effects potentially related to LBG in a very lim-
ited number of preterm or low birth weight infants possibly due
to an incomplete gastrointestinal maturation during the ﬁrst few
weeks of life.
Altogether, it can be concluded that the consumption of locust
bean gum is safe for use under medical supervision as thickener
in infant formulas for treatment of uncomplicated but frequent
troublesome regurgitation in term infants. It should not be used
in preterm and low birth weight infants below the age of 12 weeks.
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